These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 38339274)

  • 1. Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.
    Maekawa S; Takata R; Obara W
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
    Isaacsson Velho P; Carducci MA
    Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
    Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
    Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor-Related Non-coding RNAs in Prostate Cancer.
    Yang Y; Liu KY; Liu Q; Cao Q
    Front Cell Dev Biol; 2021; 9():660853. PubMed ID: 33869227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
    Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.
    Tortorella E; Giantulli S; Sciarra A; Silvestri I
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
    Frank S; Nelson P; Vasioukhin V
    F1000Res; 2018; 7():. PubMed ID: 30135717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.
    Luo J; Wang D; Wan X; Xu Y; Lu Y; Kong Z; Li D; Gu W; Wang C; Li Y; Ji C; Gu S; Xu Y
    Onco Targets Ther; 2020; 13():9257-9267. PubMed ID: 32982312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.
    Zhu W; Wan F; Xu W; Liu Z; Wang J; Zhang H; Huang S; Ye D
    Clin Transl Med; 2022 Sep; 12(9):e1028. PubMed ID: 36169095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications.
    Pisano C; Tucci M; Di Stefano RF; Turco F; Scagliotti GV; Di Maio M; Buttigliero C
    Crit Rev Oncol Hematol; 2021 Jan; 157():103185. PubMed ID: 33341506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1.
    Makino Y; Kamiyama Y; Brown JB; Tanaka T; Murakami R; Teramoto Y; Goto T; Akamatsu S; Terada N; Inoue T; Kodama T; Ogawa O; Kobayashi T
    Commun Biol; 2022 Apr; 5(1):299. PubMed ID: 35365763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells.
    Luo H; Liu Y; Li Y; Zhang C; Yu B; Shao C
    FASEB J; 2022 Sep; 36(9):e22495. PubMed ID: 35947121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
    Sun R; Wei T; Ding D; Zhang J; Chen S; He HH; Wang L; Huang H
    Proc Natl Acad Sci U S A; 2022 Sep; 119(39):e2205509119. PubMed ID: 36129942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.